The great promise of biosimilars is their ability to provide high-quality treatment at a reduced cost, thereby producing cost savings that can be reapplied. But how are healthcare systems around the globe utilizing those cost savings? During the International Society for Pharmacoeconomics and Outcomes Research 2019 meeting, held this week in Copenhagen, Denmark, several teams of researchers reported on how biosimilars are impacting international markets, and how they could provide headroom for new, expensive treatments.
The great promise of biosimilars is their ability to provide high-quality treatment at a reduced cost, thereby producing cost savings that can be reapplied. But how are healthcare systems around the globe utilizing those cost savings? During the International Society for Pharmacoeconomics and Outcomes Research 2019 meeting, held this week in Copenhagen, Denmark, several teams of researchers reported on how biosimilars are impacting international markets, and how they could provide headroom for new, expensive treatments.
In the Czech Republic, biologics are reimbursed at 1 price per group. When biosimilars launch, they are reimbursed at 30% lower than the originator product, and as a result, all products in the same group also drop in price by 30%. Researchers from the country’s State Institute for Drug Control reported on their analysis of the change in consumption—and the change in cost—of anti—tumor necrosis factor (anti-TNF) agents after the first biosimilar, infliximab, became available in 2013.1
Using publicly available data, the team found that consumption of anti-TNFs increased by 87% over 5 years, with infliximab and adalimumab being the most commonly used. In 2018, biosimilars had reached 33% of all market share for anti-TNFs, and biosimilar infliximab overtook the reference in terms of use in 2017.
According to the authors, the availability of a biosimilar infliximab has helped lower unit costs over time, and has allowed for improved access to therapy overall.
Second, a team discussed their assessment of market dynamics in France, the United Kingdom, Japan, and the Republic of Korea.2 They used MIDAS-IQVIA data from 2012 to 2018 to assess the sales value and volume for the originator and biosimilar infliximab products available in these countries, and found that the introduction of a biosimilar increased the Korean infliximab market’s value 2.5-fold, and the French and UK markets’ value by 1.2-fold. The Japanese market’s value decreased, however, 0.9 times.
Additionally, in the Korean market, the reference product saw its sales value increase after biosimilar entry, suggesting an expansion of the market for infliximab after the cost-saving biosimilars were introduced.
Finally, UK researchers reported that biosimilar savings could be the key to paying for chimeric antigen receptor (CAR) T-cell therapies and gene therapies in the country’s National Health Service (NHS).3
CAR-T and gene therapies can offer transformational benefits for patients who typically have unmet needs, say the authors, but affordability is still a challenge that needs to be addressed, and biosimilars could play a crucial role. According to the authors, the NHS reaped £200 million (approximately USD $257) from biosimilar infliximab, rituximab, and etanercept alone, and after the launch of biosimilar adalimumab, an additional $300 million (approximately USD $385 million) are expected by 2021.
Approximately 200 patients each year are expected to be eligible for one of the CAR-T therapies, which have UK list prices of £300,000 (approximately USD $385,000) and £282,000 (approximately USD $362,000), respectively. Cumulatively, the budget impact of treating eligible patients with CAR-T therapies is £116 million (approximately USD $149 million) annually.
According to the authors, the savings produced by biosimilar use significantly outweigh the budget impact of introducing CAR-T treatments, and the affordability of new drug classes may be achievable with increased focus on using biosimilars.
References
1. Chytilová P, Haluska M, Mahovská R, et al. TNF-alpha inhibitors in the Czech Republic—how biosimilars affect overall consumption and costs? Presented at: ISPOR Europe 2019; November 2-6, 2019; Copenhagen, Denmark. Abstract PBI13.
2. Kim Y, Kwon HY, Godman B, Moorkens E, Simoens S, Bae S. Uptake of biosimilar infliximab—budget savings or market expansion across countries? Presented at: ISPOR Europe 2019; November 2-6, 2019; Copenhagen, Denmark. Abstract PBI45.
3. Ivonova H, Macaulay R. Unlocking access to transformational CAR-T cell and gene therapies. Are biosimilars the key? Presented at: ISPOR Europe 2019; November 2-6, 2019; Copenhagen, Denmark. Abstract PMU64.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Oncology Biosimilars Cut Costs; Diabetes and Other Diseases Could Follow
May 6th 2025Shreehas P. Tambe, MD, highlighted the significant potential for biosimilars to expand into other disease areas like diabetes, offering crucial cost-saving solutions amid a rising global burden of noncommunicable diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
FDA's Expanded Access: From Laetrile to Right to Try, Ethical Debates Over Early Drug Access
April 28th 2025Christopher T. Robertson, JD, PhD, reviewed the history and ethical landscape of providing access to drugs before FDA approval, highlighting the crucial role of clinical trials and ethical safeguards at the 2025 Festival of Biologics USA.